KRAS and neoplasm: However, the number of tumours scoring positive for infiltrating granulocytes was higher in KRAS mutant compared with KRAS wild-type tumours (18% within the KRAS mutant versus 10% within KRAS wild-type cohort); in addition, less cases of KRAS mutant tumours scored positive for lymphocyte infiltration compared with KRAS wild-type tumours (31% within the KRAS mutant versus 48% in KRAS wild-type cohort; Supplementary Fig. 3e).